WO2006085033A3 - Pharmaceutical compositions for the treatment of prostate cancer - Google Patents

Pharmaceutical compositions for the treatment of prostate cancer Download PDF

Info

Publication number
WO2006085033A3
WO2006085033A3 PCT/FR2006/050117 FR2006050117W WO2006085033A3 WO 2006085033 A3 WO2006085033 A3 WO 2006085033A3 FR 2006050117 W FR2006050117 W FR 2006050117W WO 2006085033 A3 WO2006085033 A3 WO 2006085033A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
prostate cancer
pharmaceutical compositions
pharmaceutical composition
relates
Prior art date
Application number
PCT/FR2006/050117
Other languages
French (fr)
Other versions
WO2006085033A2 (en
Inventor
Olivier Cussenot
Guy Vallancien
Gaelle Fromont
Original Assignee
Ct De Rech Pour Les Pathologie
Olivier Cussenot
Guy Vallancien
Gaelle Fromont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Rech Pour Les Pathologie, Olivier Cussenot, Guy Vallancien, Gaelle Fromont filed Critical Ct De Rech Pour Les Pathologie
Priority to EP06709496A priority Critical patent/EP1851549A2/en
Publication of WO2006085033A2 publication Critical patent/WO2006085033A2/en
Publication of WO2006085033A3 publication Critical patent/WO2006085033A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a pharmaceutical composition, comprising a compound with a negative regulatory effect on the expression of protein BCAR-1, together with at least one acceptable pharmaceutical vehicle. Said pharmaceutical composition is particularly of use for the treatment of prostate cancers even when the above have become resistant to treatment by anti-androgenic compounds. The invention further relates to methods for detection and assessment of the malignancy of a prostate cancer in vitro.
PCT/FR2006/050117 2005-02-09 2006-02-09 Pharmaceutical compositions for the treatment of prostate cancer WO2006085033A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06709496A EP1851549A2 (en) 2005-02-09 2006-02-09 Pharmaceutical compositions for the treatment of prostate cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0550387A FR2881830B1 (en) 2005-02-09 2005-02-09 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER
FR0550387 2005-02-09

Publications (2)

Publication Number Publication Date
WO2006085033A2 WO2006085033A2 (en) 2006-08-17
WO2006085033A3 true WO2006085033A3 (en) 2007-01-11

Family

ID=34955116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/050117 WO2006085033A2 (en) 2005-02-09 2006-02-09 Pharmaceutical compositions for the treatment of prostate cancer

Country Status (3)

Country Link
EP (1) EP1851549A2 (en)
FR (1) FR2881830B1 (en)
WO (1) WO2006085033A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006831A2 (en) * 1997-07-29 1999-02-11 Dorssers Lambert C J Breast cancer resistance genes, methods for their detection and uses thereof
WO2003068054A2 (en) * 2002-02-13 2003-08-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Identification of ovarian cancer tumor markers and therapeutic targets

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006831A2 (en) * 1997-07-29 1999-02-11 Dorssers Lambert C J Breast cancer resistance genes, methods for their detection and uses thereof
WO2003068054A2 (en) * 2002-02-13 2003-08-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Identification of ovarian cancer tumor markers and therapeutic targets

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DORSSERS LAMBERT C J ET AL: "The prognostic value of BCAR1 in patients with primary breast cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 15 SEP 2004, vol. 10, no. 18 Pt 1, 15 September 2004 (2004-09-15), pages 6194 - 6202, XP002391647, ISSN: 1078-0432 *
GAO B ET AL: "Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells.", FEBS LETTERS. 19 JAN 2001, vol. 488, no. 3, 19 January 2001 (2001-01-19), pages 179 - 184, XP002391648, ISSN: 0014-5793 *
NIU HUI-LIN ET AL: "[Recent advances on molecular pathology of prostate carcinoma]", AI ZHENG = AIZHENG = CHINESE JOURNAL OF CANCER. MAY 2003, vol. 22, no. 5, May 2003 (2003-05-01), pages 552 - 556, XP002346170, ISSN: 1000-467X *

Also Published As

Publication number Publication date
FR2881830B1 (en) 2007-05-04
FR2881830A1 (en) 2006-08-11
EP1851549A2 (en) 2007-11-07
WO2006085033A2 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
WO2006113703A3 (en) Carboline derivatives useful in the treatment of cancer
NO2017019I2 (en) Enzalutamide or a pharmaceutically acceptable salt thereof
CL2007002316A1 (en) COMPOUNDS DERIVED FROM PYRIMIDINE, PI3K INHIBITORS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN PROLIFERATIVE DISEASES AS CANCER.
IN2012DN01964A (en)
WO2008079988A3 (en) Quinazolines for pdk1 inhibition
TWI317619B (en) Composition for the improvement of liver function, the reduction of serum ethanol level and antioxidant activity enhancement
WO2007053573A3 (en) Treatment of cancer with sorafenib
WO2006119365A3 (en) Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
JO2848B1 (en) Organic Compounds
CL2008000785A1 (en) Compounds derived from 4 - ((7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido [4,5-b] [1,4] diazepin-2- yl) amino) -3-methoxybenzamide; intermediate compound; pharmaceutical composition, useful to treat cancer.
WO2008052005A3 (en) Compounds and methods for treating estrogen receptor-related diseases
WO2006089087A9 (en) Compositions, kits and methods for identification, assessment, prevention and therapy of cancer
ECSP088745A (en) SUBSTITUTED DERIVATIVES OF CHROMANOL AND ITS USE
WO2008002672A3 (en) Targets for use in diagnosis, prognosis and therapy of cancer
WO2005070043A3 (en) Methods for treating non-melanoma cancers with paba
WO2006028963A3 (en) Substituted heterocyclic compounds and uses thereof
MX2007002525A (en) Diphenylethylene compounds and uses thereof.
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
WO2006096759A3 (en) Methods and compositions for treating cancer
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2007100920A3 (en) Diagnosis and treatment of prostate cancer
WO2006102375A3 (en) Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006709496

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2006709496

Country of ref document: EP